Home > Publications database > The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition. > print

001     143668
005     20240229112602.0
024 7 _ |a 10.1093/annonc/mdz121
|2 doi
024 7 _ |a pmid:31089709
|2 pmid
024 7 _ |a 0923-7534
|2 ISSN
024 7 _ |a 1569-8041
|2 ISSN
024 7 _ |a altmetric:58826730
|2 altmetric
037 _ _ |a DKFZ-2019-01242
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Smith Byrne, K.
|b 0
245 _ _ |a The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition.
260 _ _ |a Oxford
|c 2019
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1566563939_30392
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Microseminoprotein-beta (MSP), a protein secreted by the prostate epithelium, may have a protective role in the development of prostate cancer. The only previous prospective study found a 2% reduced prostate cancer risk per unit increase in MSP. This work investigates the association of MSP with prostate cancer risk using observational and Mendelian randomization (MR) methods.A nested case-control study was conducted with the European Prospective Investigation into Cancer and Nutrition (EPIC) with 1871 cases and 1871 matched controls. Conditional logistic regression analysis was used to investigate the association of pre-diagnostic circulating MSP with risk of incident prostate cancer overall and by tumour subtype. EPIC-derived estimates were combined with published data to calculate an MR estimate using two-sample inverse-variance method.Plasma MSP concentrations were inversely associated with prostate cancer risk after adjusting for total prostate-specific antigen concentration [odds ratio (OR) highest versus lowest fourth of MSP = 0.65, 95% confidence interval (CI) 0.51-0.84, Ptrend = 0.001]. No heterogeneity in this association was observed by tumour stage or histological grade. Plasma MSP concentrations were 66% lower in rs10993994 TT compared with CC homozygotes (per allele difference in MSP: 6.09 ng/ml, 95% CI 5.56-6.61, r2=0.42). MR analyses supported a potentially causal protective association of MSP with prostate cancer risk (OR per 1 ng/ml increase in MSP for MR: 0.96, 95% CI 0.95-0.97 versus EPIC observational: 0.98, 95% CI 0.97-0.99). Limitations include lack of complete tumour subtype information and more complete information on the biological function of MSP.In this large prospective European study and using MR analyses, men with high circulating MSP concentration have a lower risk of prostate cancer. MSP may play a causally protective role in prostate cancer.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Appleby, P. N.
|b 1
700 1 _ |a Key, T. J.
|b 2
700 1 _ |a Holmes, M. V.
|b 3
700 1 _ |a Fensom, G. K.
|b 4
700 1 _ |a Agudo, A.
|b 5
700 1 _ |a Ardanaz, E.
|b 6
700 1 _ |a Boeing, H.
|b 7
700 1 _ |a Bueno-de-Mesquita, H. B.
|b 8
700 1 _ |a Chirlaque, M. D.
|b 9
700 1 _ |a Kaaks, R.
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 10
|u dkfz
700 1 _ |a Larrañaga, N.
|b 11
700 1 _ |a Palli, D.
|b 12
700 1 _ |a Perez-Cornago, A.
|b 13
700 1 _ |a Quirós, J. R.
|b 14
700 1 _ |a Ricceri, F.
|b 15
700 1 _ |a Sánchez, M. J.
|b 16
700 1 _ |a Tagliabue, G.
|b 17
700 1 _ |a Tsilidis, K. K.
|b 18
700 1 _ |a Tumino, R.
|b 19
700 1 _ |a Fortner, R. T.
|b 20
700 1 _ |a Ferrari, P.
|b 21
700 1 _ |a Consortium, PRACTICAL
|b 22
|e Collaboration Author
700 1 _ |a Riboli, E.
|b 23
700 1 _ |a Lilja, H.
|b 24
700 1 _ |a Travis, R. C.
|b 25
773 _ _ |a 10.1093/annonc/mdz121
|g p. mdz121
|0 PERI:(DE-600)2003498-2
|n 6
|p 983-989
|t Annals of oncology
|v 30
|y 2019
|x 1569-8041
909 C O |o oai:inrepo02.dkfz.de:143668
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANN ONCOL : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ANN ONCOL : 2017
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebserkrankungen
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21